On September 30, 2022, the FDA released a statement describing their plan to promote the long-term stability of the supply chain of infant formula across the United States and to maintain a consistent supply of a variety of products. To do so, the FDA will continue to exercise enforcement discretion for formula manufacturers meeting predetermined criteria. Enforcement discretion allows the FDA to elect to suspend enforcement of certain approval requirements when the risk is low to patients. Manufacturers under this guidance will be allowed to market and import certain formulas while they work to meet all U.S. regulatory requirements. The goal of this policy is to diversify the sources of infant formula so that it is less likely to affect consumers should there be disruption in production from one or more manufacturers. To date, the FDA has issued 16 enforcement discretion letters to eight companies in nine countries, resulting in an increase in supply that is available to U.S. consumers. The initial enforcement discretion guidance announced in May 2022 to address the baby formula shortage was set to expire on November 14, 2022, but has since been extended to January 6, 2023, and may be extended longer if needed. It is worth noting that all companies that market infant formula in the U.S., including the eight companies who received enforcement discretion letters, must comply with all regulations such as safety, nutrient adequacy, labeling and packaging requirements. The FDA has stated that consumers should have the utmost confidence in the infant formula that is being marketed. Even with enforcement discretion, companies are still subject to inspection and must provide the FDA with details about the product’s nutritional adequacy and safety, microbiological testing, labeling information and manufacturing facility practices. There are educational resources and videos available to consumers who are interested in learning more about this topic.